183 related articles for article (PubMed ID: 24359499)
1. The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer.
Gupta K; Elkon J; El-Bahesh E; Aragon-Ching JB
Anticancer Agents Med Chem; 2016; 16(9):1166-71. PubMed ID: 24359499
[TBL] [Abstract][Full Text] [Related]
2. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care.
Heidenreich A; Pfister D
Eur Urol; 2012 Dec; 62(6):1201-4. PubMed ID: 22964168
[No Abstract] [Full Text] [Related]
3. Should docetaxel be administered earlier in prostate cancer therapy?
Graff JN; Beer TM
Expert Rev Anticancer Ther; 2015; 15(9):977-9. PubMed ID: 26223224
[TBL] [Abstract][Full Text] [Related]
4. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
5. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
6. Will chemotherapy change the management of prostate cancer?
Gilson C; Sydes MR; Chowdhury S
BJU Int; 2016 Aug; 118(2):190-2. PubMed ID: 26696125
[No Abstract] [Full Text] [Related]
7. Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer.
Dreicer R
Urol Oncol; 2008; 26(4):426-9. PubMed ID: 18593622
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; George DJ
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
[TBL] [Abstract][Full Text] [Related]
9. [Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
Ohlmann CH; Goebell PJ; Grimm MO; Klier J; König F; Machtens S; Schostak M; Schrader AJ; Albers P
Urologe A; 2017 Dec; 56(12):1597-1602. PubMed ID: 28695241
[TBL] [Abstract][Full Text] [Related]
10. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?
Mita AC; Figlin R; Mita MM
Clin Cancer Res; 2012 Dec; 18(24):6574-9. PubMed ID: 23091116
[TBL] [Abstract][Full Text] [Related]
11. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Lheureux S; Joly F
Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
[TBL] [Abstract][Full Text] [Related]
12. Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Ansari J; Hussain SA; Alhasso A; Mahmood R; Ansari A; Glaholm J
Anticancer Agents Med Chem; 2011 Mar; 11(3):296-306. PubMed ID: 21426298
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel for the treatment of prostate cancer.
Michielsen DP; Braeckman JG; Denis L
Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025
[TBL] [Abstract][Full Text] [Related]
14. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.
Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342
[TBL] [Abstract][Full Text] [Related]
15. Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sartor O
Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
[TBL] [Abstract][Full Text] [Related]
16. Optimal timing of chemotherapy in androgen independent prostate cancer.
Schnadig ID; Beer TM
Urol Oncol; 2009; 27(1):97-100. PubMed ID: 19111808
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel for hormone-sensitive metastatic prostate cancer.
Baker H
Lancet Oncol; 2015 Sep; 16(9):e432. PubMed ID: 26278160
[No Abstract] [Full Text] [Related]
18. Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel.
Lovett R; Kelly V; Goodall M; Adler AI
Lancet Oncol; 2016 Jul; 17(7):872-873. PubMed ID: 27234583
[No Abstract] [Full Text] [Related]
19. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
[TBL] [Abstract][Full Text] [Related]
20. Re: Axel Heidenreich, David Pfister. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Eur Urol 2012;62:1201-4.
Brookman-May S; Tombal B; Joniau S
Eur Urol; 2013 Sep; 64(3):e62-4. PubMed ID: 23582882
[No Abstract] [Full Text] [Related]
[Next] [New Search]